BRPI0514861A - furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila - Google Patents

furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila

Info

Publication number
BRPI0514861A
BRPI0514861A BRPI0514861-8A BRPI0514861A BRPI0514861A BR PI0514861 A BRPI0514861 A BR PI0514861A BR PI0514861 A BRPI0514861 A BR PI0514861A BR PI0514861 A BRPI0514861 A BR PI0514861A
Authority
BR
Brazil
Prior art keywords
amino
dimethylphenyl
benzonitrile
cyanoethenyl
pyrimidinyl
Prior art date
Application number
BRPI0514861-8A
Other languages
English (en)
Inventor
Paul Theodoor Agnes Stevens
Jozef Peeters
Roger Petrus Gerebe Vandecruys
Alfred Elisabeth Stappers
Alex Herman Copmans
Original Assignee
Janssen Pharmaceutica Nv
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Application filed by Janssen Pharmaceutica Nv, Tibotec Pharm Ltd filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2005/054341 external-priority patent/WO2006024667A1/en
Publication of BRPI0514861A publication Critical patent/BRPI0514861A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

FURAMATO DE 4-((-((4-(2-CIANOETENIL)-2.6-DIMETILFENIL)AMINO)-2-PIRIMIDI NIL) AMINO)BENZONITRILA. A presente invenção refere-se ao sal de fumarato de 4-¢¢4-¢¢4-(2-cianoetenil)-2,6-dimetilfenil!amino)-2-pirimidinil!amino!ben zonitrila, sendo que as composições farmacêuticas compreendem como um ingrediente ativo o dito sal, e aos processos para a sua preparação.
BRPI0514861-8A 2004-09-02 2005-09-02 furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila BRPI0514861A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP05101447 2005-02-25
PCT/EP2005/054341 WO2006024667A1 (en) 2004-09-02 2005-09-02 Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile

Publications (1)

Publication Number Publication Date
BRPI0514861A true BRPI0514861A (pt) 2008-06-24

Family

ID=38091631

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514861-8A BRPI0514861A (pt) 2004-09-02 2005-09-02 furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila

Country Status (19)

Country Link
US (3) US20090215804A1 (pt)
EP (1) EP1789139B1 (pt)
JP (1) JP4922937B2 (pt)
KR (1) KR101276571B1 (pt)
AP (1) AP2487A (pt)
AT (1) ATE550074T1 (pt)
AU (1) AU2005279157B2 (pt)
BR (1) BRPI0514861A (pt)
CA (1) CA2577273C (pt)
CR (1) CR9032A (pt)
DK (1) DK1789139T3 (pt)
EA (1) EA011036B1 (pt)
ES (1) ES2384715T3 (pt)
HR (1) HRP20120499T1 (pt)
IL (1) IL181649A0 (pt)
MX (1) MX2007002594A (pt)
NI (1) NI200700069A (pt)
NO (1) NO339788B1 (pt)
SI (1) SI1789139T1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702044B1 (en) 2011-04-25 2017-03-22 Hetero Research Foundation Process for rilpivirine
CA3156674A1 (en) * 2019-10-10 2021-04-15 Axcella Health Inc. Reduced volume formulations including amino acid entities

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498419A (en) * 1994-06-03 1996-03-12 Pars; Harry G. Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric
CA2275604A1 (en) * 1997-01-03 1998-07-09 Kenneth Iain Cumming Sustained release cisapride mini-tablet formulation
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CN102702111B (zh) * 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
PL227577B1 (pl) * 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
WO2004071374A2 (en) * 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions

Also Published As

Publication number Publication date
CA2577273A1 (en) 2006-03-09
US20180116964A1 (en) 2018-05-03
AU2005279157A1 (en) 2006-03-09
NO20071720L (no) 2007-04-02
JP4922937B2 (ja) 2012-04-25
EP1789139B1 (en) 2012-03-21
AU2005279157B2 (en) 2011-07-14
EA011036B1 (ru) 2008-12-30
MX2007002594A (es) 2007-04-25
JP2008511591A (ja) 2008-04-17
AP2007003933A0 (en) 2007-04-30
NO339788B1 (no) 2017-01-30
ATE550074T1 (de) 2012-04-15
US20090215804A1 (en) 2009-08-27
SI1789139T1 (sl) 2012-08-31
EP1789139A1 (en) 2007-05-30
KR101276571B1 (ko) 2013-06-18
HK1112862A1 (en) 2008-09-19
IL181649A0 (en) 2007-07-04
DK1789139T3 (da) 2012-07-09
CR9032A (es) 2009-07-30
ES2384715T3 (es) 2012-07-11
US20110150996A1 (en) 2011-06-23
AP2487A (en) 2012-10-03
HRP20120499T1 (hr) 2012-07-31
NI200700069A (es) 2015-12-10
EA200700534A1 (ru) 2007-08-31
CA2577273C (en) 2013-11-19
KR20070053284A (ko) 2007-05-23

Similar Documents

Publication Publication Date Title
NI200700068A (es) Clorhidrato de 4-[[4-[[4-(2-cianoetenil)-2,6- dimetilfenil]amino]-2- pirimidinil]amino] benzonitrilo
CL2012000509A1 (es) Formulacion concentrada acuosa para la proteccion de plantas porque comprende 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida; uso de la formulacion; método de control de la vegetacion no deseada.
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
DOP2011000360A (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoico y acido monobenzoico de 2-(4((2-amino-4-metil-6-(pentilamino) primidin-5-ii)metil) fenil) acetato de 4-(dimetilamino) butilo
CL2012000507A1 (es) Formulacion que comprende -2cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida, un tensioactivo no ionico seleccionado de copolimeros de bloque de polioxietileno-polioxi-alquileno, un tensioactivoanionico que comprende al menos un grupo arilsulfato; y agua; uso de la formulacion para controlar vegetacion no deseada; y metodo de control asociado.
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI1006162A2 (pt) "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
PE20150998A1 (es) Inhibidores de histona demetilasas
BRPI0509184A (pt) composições farmacêuticas
BRPI0514731A (pt) derivados de pirimidina
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
HN2006029142A (es) Proceso
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
AR054779A1 (es) N-(2,2-dimetilpropil)-6-{3-fluoro-5-[(3-isoxazolilamino)carbonil]-2-metilfenil}-3-piridinacarboxamida
CL2012001248A1 (es) Compuestos de amidoacetonitrilo que tiene actividad pesticida; uso de dicho compuesto para el control de parasitos en animales de sangre caliente.
NI200700069A (es) Fumarato de 4-((4-((4- (2-cianoetenil)-2,6-dimetilfenil)amino)-2- pirimidinil) amino) benzonitrilo
CL2007003392A1 (es) Compuestos derivados de 2-{[2-(amina sustituida)etil]sulfonil}etil n,n,n',n'-tetrakis(2-cloroetil) fosforodiamidatos; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BRPI0819983A2 (pt) Processo para a preparação de derivados de ácido 2-(amino primário/secundário)hidrocarbil)carbamoil-7-oxo-2, 6-diaza-biciclo-[3.2.0]-heptano-6-sulfônico
BR112022010019A2 (pt) Processos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
UA92469C2 (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
PA8626601A1 (es) Formas de dosificacion y composiciones farmaceuticas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JANSSEN PHARMACEUTICA N.V. (BE)

Free format text: TRANSFERIDO DE: TIBOTEC PHARMACEUTICALS LTD.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/505 (2006.01), A61P 31/18 (2006.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL